Audentes Therapeutics Obtains $75,000,000 New Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8dcfedb6-6193-4a3d-b8f2-e6e6691e44f5
Date 7/20/2016
Company Name Audentes Therapeutics
Mailing Address 101 Montgomery Street. San Francisco, CA 94104 USA
Company Description Audentes Therapeutics (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.
Proceeds Purposes We currently intend to use the net proceeds from this offering for the following purposes: approximately $18.0 to $20.0 million to advance AT132 for the treatment of XLMTM through preliminary results from a Phase 1/2 clinical trial expected in the fourth quarter of 2017; approximately $13.0 to $15.0 million to advance AT342 for the treatment of Crigler-Najjar through preliminary results from a Phase 1/2 clinical trial expected in the fourth quarter of 2017; approximately $3.0 to $5.0 million to advance preclinical development of AT982 for the treatment of Pompe disease through preliminary results from a Phase 1/2 clinical trial expected in the second half of 2017; approximately $3.0 to $5.0 million to advance preclinical development of AT307 for the treatment of CASQ2-CPVT through submission of an IND or CTA in 2017; approximately $7.0 to $10.0 million to operate and expand our internal manufacturing facility; and the remainder for working capital and other general corporate purposes,